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Production in Different Age Cohorts following 2009 H1N1 Influenza
Virus Vaccination
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Modeling, University of Rochester Medical Center, Rochester, New York, USAd; Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USAe;
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USAf; Laboratory of Infectious Diseases, National
Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USAg

The 2009 pandemic H1N1 (pH1N1) influenza virus carried a swine-origin hemagglutinin (HA) that was closely related to the
HAs of pre-1947 H1N1 viruses but highly divergent from the HAs of recently circulating H1N1 strains. Consequently, prior exposure to pH1N1-like viruses was mostly limited to individuals over the age of about 60 years. We related age and associated differences in immune history to the B cell response to an inactivated monovalent pH1N1 vaccine given intramuscularly to subjects
in three age cohorts: 18 to 32 years, 60 to 69 years, and >70 years. The day 0 pH1N1-specific hemagglutination inhibition (HAI)
and microneutralization (MN) titers were generally higher in the older cohorts, consistent with greater prevaccination exposure
to pH1N1-like viruses. Most subjects in each cohort responded well to vaccination, with early formation of circulating virusspecific antibody (Ab)-secreting cells and >4-fold increases in HAI and MN titers. However, the response was strongest in the
18- to 32-year cohort. Circulating levels of HA stalk-reactive Abs were increased after vaccination, especially in the 18- to 32-year
cohort, raising the possibility of elevated levels of cross-reactive neutralizing Abs. In the young cohort, an increase in MN activity against the seasonal influenza virus A/Brisbane/59/07 after vaccination was generally associated with an increase in the antiBrisbane/59/07 HAI titer, suggesting an effect mediated primarily by HA head-reactive rather than stalk-reactive Abs. Our findings support recent proposals that immunization with a relatively novel HA favors the induction of Abs against conserved
epitopes. They also emphasize the need to clarify how the level of circulating stalk-reactive Abs relates to resistance to influenza.

A

critical determinant of clinical protection against influenza is
the presence of preexisting functional antibodies (Abs) specific for viral hemagglutinin (HA), as detected in the traditional
hemagglutination inhibition (HAI) assay. This is emphasized by
the influenza pandemic of 1968, when an HA shift to H3 in a
circulating H2N2 strain was the only structural protein change
required to generate the pandemic virus. In 2009, the initial cases
of human infection with a novel H1N1 influenza A virus of swine
origin were soon followed by the rapid global spread of the virus
and the declaration of an influenza pandemic (1, 2). The 2009
pandemic H1N1 (pH1N1) virus carried a classical swine H1 HA
that was highly divergent from the HAs of seasonal H1N1 influenza A viruses circulating at the time. As a result, the neutralizing
Abs generated by infection or vaccination with the recent seasonal
H1N1 viruses had little activity against the pH1N1 virus (3, 4).
The classical swine H1 HA (as carried by the 2009 pH1N1
virus) and that of the 1918 human pandemic virus are antigenically similar (5), likely reflecting the establishment of an aviansource H1N1 virus in human and swine populations in 1918 (6).
Since then, H1N1 viruses have been maintained in North American swine with little change in the HA. The H1N1 viruses that
commenced circulating in humans in 1918 were subjected to the
selective pressures of host immunity, resulting in a progressive
antigenic drift in the HA. However, significant antigenic relatedness with the H1 of the 1918 virus was probably maintained in
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circulating H1N1 viruses until at least 1947 (7). Consequently, a
high proportion of individuals over the age of about 60 years carried Abs that neutralized the 2009 pH1N1 virus and were largely
spared significant disease in the 2009 pandemic (8). Recipients of
the A/New Jersey/76 (H1N1) swine influenza vaccine in 1976 also
carried pH1N1-neutralizing Abs because of the close antigenic
relatedness of the H1 HA molecules (3, 9).
Studies of responses to inactivated pH1N1 vaccines have demonstrated that a single unadjuvanted dose induces protective HAI
Ab levels in the majority of adults of all ages (10–13). These include young adults without preexisting HAI activity against
pH1N1, indicating that exposure to recent seasonal H1N1 viruses
is sufficient to prime for a B cell response to the pH1N1 virus. A
recent analysis identified qualitative differences between the re-
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sponses of young and elderly adults to pH1N1 vaccination consistent with differences in the history of exposure to influenza virus
antigens (13). In the elderly subjects, Abs induced against the HA
globular head domain displayed a broader epitope repertoire and
bound with higher affinity. This probably reflects the selection
and activation of memory B cells (MBCs) present only in elderly
adults and generated by past exposure to related HA molecules.
In recent studies, pH1N1 vaccination preferentially induced
broadly cross-reactive Abs, including HA head-reactive Abs that
neutralized a range of H1N1 strains and HA stalk-reactive Abs
with neutralizing activity against viruses of different subtypes (14–
17). This contrasted with the largely strain-specific Ab response to
seasonal influenza vaccination (16, 18, 19). In models proposed to
explain these observations (14–16), the Ab response to the seasonal vaccine largely reflects activation of abundant memory B
cells that recognize immunodominant (and variable) epitopes in
the HA head. The lower number of memory B cells specific for
conserved epitopes in the HA head and stem are outcompeted
when the antigen is limiting, and they do not contribute to the
response. The activation of memory B cells that recognize conserved subdominant HA epitopes is likely following pH1N1 vaccination in individuals who had not been exposed previously to
related viruses because the dominant HA epitopes in the pH1N1
virus are substantially novel and the memory B cells responsive to
the epitopes are lacking. Responses to the conserved HA epitopes
in the pH1N1 virus are thus likely to be pronounced in individuals
born in the period after about 1947, when related viruses were not
circulating in humans. Consistent with this, Miller and colleagues
(17) analyzed sera from non-pH1N1-exposed individuals born
after about 1947 and identified higher levels of HA stalk-reactive
Abs in recipients of the 1976 swine influenza vaccine than in individuals who did not receive the vaccine.
The current study was undertaken to relate age and immune
history to the B cell response to an inactivated pH1N1 vaccine. We
demonstrate a strong pH1N1-specific response to vaccination in
adult subjects of all ages, including a young adult cohort selected
to minimize the likelihood of prior exposure to a pH1N1-like
virus. Consistent with current models, the response in the young
cohort in particular included the production of stalk-reactive Abs.
However, increased neutralizing activity against the seasonal
H1N1 virus in the young cohort after pH1N1 vaccination appeared to be mediated primarily by HA head-reactive rather than
stalk-reactive Abs.
MATERIALS AND METHODS
Study design and participants. Healthy adult men and nonpregnant
women were enrolled in 3 age cohorts: 18 to 32 years (n ⫽ 20), 60 to 69
years (n ⫽ 20), and ⱖ70 years (n ⫽ 18). The upper age limit of 32 years for
subjects in the youngest cohort ensured that they had not received the
antigenically cross-reactive A/New Jersey/76 vaccine. Older subjects with
a known history of immunization with the A/New Jersey/76 vaccine were
excluded. Subjects with a history of laboratory-documented infection
with pH1N1 virus or immunization with a pH1N1 vaccine were ineligible
for the study. There had been pH1N1 activity in the local community
prior to commencement of the study, and we cannot exclude the possibility that the pH1N1-specific Abs in some subjects might have been generated by subclinical infection. Most subjects in each cohort reported
receiving the 2009-2010 seasonal trivalent influenza vaccine 2 to 4 months
before administration of the pH1N1 vaccine (13 of 20, 16 of 20, and 17 of
18 subjects in the 18- to 32-year, 60- to 69-year, and ⱖ70-year cohorts,
respectively). The study was conducted under a protocol approved by the
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University of Rochester Research Subjects Review Board. Informed written consent was obtained from each participant.
Subjects received a single intramuscular (i.m.) injection of inactivated
influenza A/California/07/2009 (H1N1) monovalent subunit vaccine
(Novartis). Each 0.5-ml dose contained 15 g of HA antigen. Administration of the vaccine (study day 0) took place from January to March
2010. Blood was collected from each subject on days 0, 7 (range, 6 to 8),
and 28. The day 0 and day 28 samples provided sera for analysis of circulating Abs. Nasal secretions were sampled on days 0 and 28 by spraying
saline into a nostril and absorbing fluid by nasal wick for 5 min. B cells
were enriched from the day 7 blood samples and analyzed by an enzymelinked immunosorbent spot (ELISpot) assay and flow cytometry. Baseline
values for the cellular analysis were generated from a selection of day 0
samples.
ELISpot assay for Ab-secreting cells. B cells were negatively enriched
from heparinized whole blood by treatment with a RosetteSep human
blood enrichment cocktail (Stem Cell Technologies, Vancouver, Canada),
followed by density gradient separation according to the manufacturer’s
instructions. Vaccine-specific IgG and IgA Ab-secreting cells (ASCs) were
enumerated by an ELISpot assay as described previously (20). Briefly,
Immobilon P membrane-based 96-well plates (Millipore, Billerica, MA)
were coated overnight at 4°C with a 1:10 dilution of the inactivated vaccine in phosphate-buffered saline (PBS) (100 l/well). PBS only was
added to the negative-control wells. Plates were blocked with complete
medium (RPMI 1640 supplemented with 10% heat-inactivated fetal calf
serum, 100 units/ml penicillin G, and 100 g/ml streptomycin) before
use. Enriched B cells were resuspended in complete medium containing
either alkaline phosphatase-conjugated goat anti-human IgG (H ⫹ L)
(KPL, Gaithersburg, MD) at 0.2 g/ml or alkaline phosphatase-conjugated goat anti-human IgA (KPL) at 0.2 g/ml for the detection of IgG or
IgA ASCs, respectively. Serial 2-fold dilutions of the cell suspensions were
prepared in the coated/blocked plates, and the plates were incubated for at
least 4 h at 37°C in 5% CO2. The plates were washed, and spots representing IgG or IgA ASCs were developed with a Vector Blue alkaline phosphatase substrate kit (Vector Laboratories, Burlingame, CA). Spots were
counted using a CTL ImmunoSpot plate reader and counting software
(Cellular Technology Limited, Cleveland, OH). Counts are expressed as a
frequency of CD19⫹ B cells.
Flow cytometry. Enriched B cells were stained with the following
panel of directly conjugated reagents at previously determined optimal
concentrations: anti-CD3 PE (UCHT-1), anti-CD19 fluorescein isothiocyanate (FITC) (HIB19), anti-CD20 V450 (L27), anti-CD27 allophycocyanin (APC)-H7 (M-T271), and anti-CD138 APC (MI15) (all from BD
Biosciences, San Jose, CA) and anti-CD38 phycoerythrin (PE)-Cy7
(HIT2) (eBioscience, San Diego, CA). A LIVE/DEAD fixable violet staining kit (Invitrogen, Camarillo, CA) was used to discriminate dead cells.
Data were acquired using an LSR II flow cytometer (BD Biosciences) and
analyzed using FlowJo software (TreeStar, Ashland, OR).
Hemagglutination inhibition and microneutralization assays. HAI
and microneutralization (MN) assays were performed against the 2009
pH1N1 isolate A/California/04/09 and the seasonal H1N1 virus A/Brisbane/
59/07 (Bris/07). Viruses were obtained from the Centers for Disease Control and Prevention (CDC) (Atlanta, GA) and were expanded in eggs prior
to use. HAI titers were also measured against a reassortant H6N1 virus
that expressed the HA of A/mallard/Sweden/81/02. A stock of the H6N1
reassortant virus was grown in eggs and inactivated prior to use. Anti-H6
mouse serum served as a positive control. Serum samples were pretreated by overnight incubation at 37°C with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan), followed by heating at 56°C for
30 min.
The HAI assay was based on a standard procedure (20). Briefly, serial
2-fold dilutions of pretreated sera in 96-well V-bottom microtiter plates
were mixed with 4 HA units of virus. After incubation at room temperature for 1 h, 50 l of 0.75% turkey red blood cells was added to each well
and mixed gently. Plates were then held at 4°C for a minimum of 45 min
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before the HAI titers were read. The HAI titer was defined as the reciprocal
of the highest serum dilution with no HA activity. For each sample, the
baseline HAI activity was determined by incubating only serum and red
blood cells. These titers ranged from 4 to 8 in all cohorts and were used for
calculating the fold increase in the HAI titer.
The MN assay was performed according to a protocol provided by the
CDC. Briefly, 100 50% tissue culture infective doses (TCID50s) of virus
(50 l/well) was added to serial 2-fold dilutions of pretreated sera (10
replicate wells/dilution; 50 l/well) in 96-well flat-bottom tissue culture
plates. Dilutions of virus and sera were prepared in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 1% bovine serum albumin
(BSA), antibiotics, and 20 mM HEPES (designated virus diluent). After
gentle mixing, the plates were incubated at 37°C for 1 h. MDCK cells
(1.5 ⫻ 105 cells/ml) in virus diluent were then added (100 l/well), and
the plates were incubated at 37°C for 18 to 20 h. After incubation, the wells
were washed with PBS and fixed with 80% acetone in PBS. An enzymelinked immunosorbent assay (ELISA) to detect viral nucleoprotein (NP)
expression in MDCK cells was used to identify viral replication. Briefly,
the plates were washed after fixing, and an anti-NP monoclonal antibody
(MAb) (Millipore) was added to the wells. Bound Ab was detected by the
addition of horseradish peroxidase-conjugated goat anti-mouse IgG
(KPL), followed by o-phenylenediamine dihydrochloride substrate tablets in citrate buffer (Sigma-Aldrich, St. Louis, MO). The reaction was
stopped with 0.5 M sulfuric acid, and the absorbance was read at 490 nm.
Wells were scored as positive for neutralizing activity if the absorbance
was less than the sum of the median absorbance of the virus control wells
(virus plus MDCK cells only) and the median absorbance of cell control
wells (MDCK cells only). The 50% neutralizing Ab titer (MN titer) was
determined from the proportions of positive and negative wells. An MN
titer of 5 was assigned to the samples in which the lowest dilution in the
assay (1/10) was negative.
Kinetic ELISA for nasal Abs. HA-specific IgA in nasal secretions collected by the nasal wick procedure was measured by a kinetic ELISA (21).
Briefly, 96-well ELISA plates were coated with purified 2009 pH1N1 HA
(Novartis, Liverpool, United Kingdom) and incubated at 4°C for 18 h.
The plates were washed and blocked, and then the samples extracted from
the nasal wicks were added to duplicate wells. The samples added to uncoated wells were used to determine the assay background. After incubation at 4°C for 18 h, the assay was completed by adding, in sequence,
biotinylated goat anti-human IgA (Invitrogen), streptavidin-conjugated
horseradish peroxidase (Sigma-Aldrich), and 2,2=-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) substrate (Sigma-Aldrich). The rate
of color development (milliunits of optical density [mOD]/min) was determined by readings at 414 nm taken every 9 s for 5 min using a SpectraMax Plus microplate reader (Molecular Devices, Sunnyvale, CA) and analyzed using SoftMax for Windows software (Molecular Devices). A
similar kinetic ELISA using plates coated with anti-human IgA (SouthernBiotech, Birmingham, AL) was used to measure the total IgA levels in
the nasal samples. The concentration of total IgA was calculated from a
curve constructed with an IgA standard from human colostrum (SigmaAldrich). HA-specific IgA titers were adjusted for the levels of total IgA
and are expressed as mOD/min/g total IgA.
ELISA for serum Abs. Abs reactive with the HA stalk or the intact HA
of pH1N1 were detected by an ELISA. A chimeric HA consisting of the
head domain of an H6 HA and the stalk domain of PR8 (H1) virus
(cH6/1) was generated as described previously (22). The head domain of
the chimeric HA was derived from the H6 HA of A/mallard/Sweden/81/
02. Purified full-length recombinant HA from influenza A/California/
04/09 (H1N1) (NR-15258) was obtained from NIH/NIAID Biodefense
and Emerging Infections (BEI) Resources. Immulon 4HBX 96-well plates
were coated with recombinant HA (0.05 g/well) or with BSA as a negative control. Briefly, ELISAs were completed by the addition of serial
3-fold dilutions of the test sample and then horseradish peroxidase-conjugated goat anti-human IgG (SouthernBiotech), followed by 3,3=,5,5=tetramethylbenzidine dihydrochloride (TMB) substrate (BioLegend, San
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Diego, CA). The reaction was stopped with 1 M H2SO4, and the well
absorbance was read at 450 nm. Titers are expressed as the reciprocal of
the highest dilution giving an absorbance of greater than twice the value
for a similar titration in the negative-control wells.
Statistics. For statistical analyses, data were transformed to stabilize
variances and approximate normal distributions. Log transformation was
used for IgG and IgA ASC frequencies, HAI titers, and MN titers; inverse
hyperbolic transformation 关ln共x ⫹ 兹1⫹x2兲兴 was used for the percentages of CD38high CD27high and CD38high CD138⫹ cell subsets. Analysis of
variance (ANOVA) was used for multiple between-cohort comparisons.
Repeated ANOVA was used for paired comparisons of titers collected over
time. Correlations within the cohorts were evaluated using the Spearman
correlation test. Linear regression modeling with model selection based
on the likelihood ratio test was used to assess (i) the relationship between
prevaccination pH1N1-specific Ab titers and the fold change in titer and
(ii) the relationship between early cellular measurements and the fold
change in the HAI titer. P values of ⬍0.05 were considered statistically
significant.

RESULTS

Antigen-specific B cell response to pH1N1 vaccination. The antigen-specific B cell response to vaccination was evaluated in subjects in three age cohorts: 18 to 32 years, 60 to 69 years, and ⱖ70
years. The pre- and postvaccination levels of pH1N1-specific Abs
in the circulation and at the nasal mucosa were determined. In
addition, the early appearance of circulating ASCs specific for vaccine components was monitored, since a transient wave of these
cells peaking on approximately day 7 is a feature of the response to
i.m. influenza vaccination in adults (23).
Circulating and nasal wash Ab levels. Sera collected on study
days 0 and 28 were analyzed for pH1N1-specific Abs by HAI and
MN assays (Fig. 1). On day 0, the trend was for HAI titers that were
higher in the older cohorts than in the 18- to 32-year cohort, but
the difference was only significant for the 60- to 69-year cohort.
This pattern was less marked for the MN titers on day 0. Overall,
the day 0 titers were consistent with greater prevaccination exposure to pH1N1-like viruses in the older cohorts.
Vaccination resulted in a highly significant increase in the HAI
and MN titers in all cohorts (P ⬍ 0.0001 for paired comparisons of
day 0 and day 28 titers). HAI titers increased ⱖ4-fold in the majority of subjects in each cohort, indicating an effective seroresponse (Fig. 1B and D). This included 14 of the 15 subjects in the
older cohorts with HAI titers of ⱕ16 on day 0. Notably, the fold
increase in HAI and MN titers in the 18- to 32-year cohort was
significantly greater than those in the other cohorts.
We used linear regression modeling to evaluate whether the
pH1N1-specific Ab response to vaccination related to the prevaccination titers. For each cohort, there was a negative correlation
between the HAI titer on day 0 and the fold increase in the HAI
titer after vaccination (P ⫽ 0.009), suggesting a dampening of the
response by preexisting Abs. A similar trend was evident for MN
titers, but the correlations were not significant (P ⫽ 0.1697).
The nasal secretions sampled on days 0 and 28 were tested by
ELISAs for IgA Abs specific for the 2009 pH1N1 HA. Day 0 titers
were similar in all cohorts and were not significantly increased on
day 28 (Fig. 2).
Cellular responses in peripheral blood. To evaluate early ASC
formation, B cells in blood collected on day 7 were enriched to
⬎90% purity and analyzed by an ELISpot assay and flow cytometry. The majority of subjects in all cohorts responded to vaccination with vaccine-specific IgG and IgA ASC formation (Fig. 3A to
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FIG 1 Ab responses to an inactivated pH1N1 vaccine in the 18- to 32-year (circles), 60- to 69-year (diamonds), and ⱖ70-year (triangles) age cohorts. The titers of
pH1N1-specific Abs in serum on days 0 and 28 after vaccination were measured by HAI (A and B) and MN (C and D) assays. The titers on days 0 and 28 (A and C) and
fold changes in titers from days 0 to 28 (B and D) are shown for individual subjects. Bars identify geometric mean titers (GMTs) (A and C) or geometric means of fold
increases (B and D). Within-cohort statistical analyses represent paired comparisons of day 0 and day 28 titers. Only statistically significant differences are indicated: **,
P ⬍ 0.01, and ***, P ⬍ 0.001.

FIG 2 Virus-specific IgA in nasal secretions after pH1N1 vaccination. Nasal secretions sampled on days 0 and 28 after vaccination of the indicated age cohorts
(18 to 32 years, 60 to 69 years, and ⱖ70 years) were tested by an ELISA for pH1specific IgA. Titers of pH1-specific IgA (mOD/min/g total IgA) on day 0 (A) and
fold changes in the titers from days 0 to 28 (B) are shown for individual subjects.
The median values (bar) and interquartile ranges are identified.
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C). However, the IgG ASC frequency (per 106 B cells) of 9,640
(geometric mean) (95% confidence interval, 5,299 to 17,537) in
the 18- to 32-year cohort was significantly higher than the frequencies in the 60- to 69-year cohort (1,440 [829 to 2,501], P ⬍
0.0001) and the ⱖ70-year cohort (1,649 [861 to 3,160], P ⬍
0.0001). The IgA ASC frequencies in the 18- to 32-year (591 [162
to 2,151]), 60- to 69-year (362 [150 to 871]), and ⱖ70-year (168
[38 to 749]) cohorts were not significantly different.
Flow cytometric analysis of enriched CD19⫹ B cells from the
blood focused on the plasmablast population (CD19⫹ CD38high
CD27high) and a subset of plasmablasts (designated plasma cells)
that expressed the differentiation marker CD138 (CD19⫹
CD38high CD138⫹) (18, 24). These cell populations were uniformly CD20low/⫺. The day 0 plasmablast and plasma cell frequencies were similar between age cohorts and consistent with the very
low numbers of these cells present under steady-state conditions
in the peripheral blood of healthy adults (24). On day 7 after
vaccination, the frequencies of circulating plasmablasts and
plasma cells were significantly higher in the 18- to 32-year cohort
than in the 60- to 69-year and the ⱖ70-year cohorts (Fig. 3D and
E), consistent with the pattern for vaccine-specific IgG ASCs.
We applied linear modeling to evaluate whether the day 7 analysis of circulating cells by an ELISpot assay and flow cytometry was
predictive of the HAI Ab response to vaccination. In each cohort,
there was a strong positive correlation between the virus-specific
IgG ASC frequency and the fold increase in the HAI titer (Fig. 4).
The intercepts for all regression lines were zero, but the slope
for the 18- to 32-year cohort was significantly greater than those
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FIG 3 Circulating ASCs induced by pH1N1 vaccination. B cells enriched from blood were analyzed by an ELISpot assay for vaccine-specific ASCs and by flow
cytometry for ASC phenotypes. (A to C) Vaccine-specific ASCs. IgG and IgA ASC frequencies on days 6 to 8 after vaccination are shown for individual subjects
in the 18- to 32-year (A), 60- to 69-year (B), and ⱖ70-year (C) age cohorts. Vaccine-specific ASCs were not detected in the day 0 samples. (D and E) Flow
cytometric identification of ASCs. Frequencies of CD38high CD27high cells (plasmablasts) (D) and CD38high CD138⫹ cells (plasma cells) (E) represent the
percentages of CD3⫺ CD19⫹ cells. Frequencies on days 6 to 8 after vaccination are shown for individual subjects in the indicated age cohorts (18 to 32 years, 60
to 69 years, and ⱖ70 years). The median values (bars) and interquartile ranges are identified. Day 0 values did not differ between cohorts and are shown as the
means (dashed lines) and 95% confidence intervals (CIs) (shaded zones). Only statistically significant differences in the ASC frequencies are indicated: *, P ⬍
0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001.

FIG 4 Relationship between vaccine-specific IgG ASCs and the HAI response.
A linear regression model assuming different coefficients for different age cohorts was fitted to evaluate the relationship between the frequency (log 10) of
circulating vaccine-specific IgG ASCs (per 106 B cells) on days 6 to 8 after
pH1N1 vaccination and the fold change (log 2) in the pH1N1-specific HAI
titer from days 0 to 28. The likelihood ratio test indicated zero intercepts for all
regression lines (P ⫽ 0.88). The fitted model explained 87% of the variability of
the data (R2 ⬇ 0.87). For each cohort, a strong positive correlation existed
between the virus-specific IgG ASC frequency and the fold change in the HAI
titer (P ⬍ 0.0001). The slope was significantly greater for the 18- to 32-year
cohort than for the 60- to 69-year cohort (P ⬍ 0.0001) and the ⱖ70-year
cohort (P ⫽ 0.0018); the slopes for the 60- to 69-year and ⱖ70-year cohorts
were not significantly different.
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for the 60- to 69-year cohort (P ⬍ 0.0001) and the ⱖ70-year
cohort (P ⫽ 0.0018), indicating a greater fold increase in the HAI
titer for a given IgG ASC frequency in the 18- to 32-year cohort
than in the older cohorts. Plasmablast and plasma cell frequencies
were positively correlated with the fold increase in the HAI titer in
the 18- to 32-year cohort (P ⫽ 0.0351 and 0.0218 for plasmablasts
and plasma cells, respectively) but not in the older cohorts.
pH1N1 vaccination induces HA stalk-reactive Abs in young
adults. We used an ELISA strategy to investigate the production of
stalk-binding Abs in the three age cohorts after pH1N1 vaccination. A chimeric HA molecule (cH6/1) with an exotic head domain that was novel to most of the human population was used as
a coating reagent so that bound Abs were most likely directed
against the stalk region. Consistent with this reasoning, all samples
collected on day 28 after vaccination were HAI negative (titers ⬍
4) against an H6N1 virus that carried the same H6 head domain as
cH6/1. Pica and colleagues (22) found little reactivity with cH6/1
in sera from non-pH1N1-infected adults. However, we found a
greater range of cH6/1-binding activity, including low activity, in
a preliminary analysis of sera from adults in a healthy-donor program (data not shown).
IgG Abs that bound to cH6/1 were present in all subjects on day
0, with significantly higher titers in the older cohorts (Fig. 5A).
The increase in anti-cH6/1 IgG titers on day 28 was highly significant in the 18- to 32-year cohort (P ⬍ 0.0001 for a paired comparison of day 0 and day 28 titers), indicating the induction of Abs
reactive with the HA stalk. In addition, the fold increase in anticH6/1 IgG titers in the 18- to 32-year cohort was significantly
greater than those in the other cohorts (Fig. 5B). There was a
strong positive correlation between the fold increase in anti-cH6/1
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FIG 5 Induction of HA stalk-reactive Abs by pH1N1 vaccination. Serum titers of IgG reactive with the chimeric HA molecule cH6/1 (A and B) or with the intact
HA (pH1) of the vaccine virus (C and D) were measured by ELISAs on days 0 and 28 after vaccination of the indicated age cohorts (18 to 32 years [circles], 60
to 69 years [diamonds], and ⱖ70 years [triangles]). The titers were determined by endpoint titration and are expressed as the reciprocal of the serum dilution.
Fold changes in the titer were calculated from OD ratios for dilutions in the linear regions of serum titration curves. The titers on day 0 (A and C) and the fold
changes in titer from days 0 to 28 (B and D) are shown for individual subjects. Bars identify geometric mean titers (GMTs) (A and C) or geometric means of the
fold increase (B and D). Only statistically significant differences are indicated: **, P ⬍ 0.01, and ***, P ⬍ 0.001.

IgG titers and the fold increase in pH1N1-specific HAI titers in the
18- to 32-year cohort (r ⫽ 0.724, P ⫽ 0.0003), indicating parallel
development of responses against HA head and stalk regions. Although cH6/1-specific IgG titers were also significantly increased on
day 28 in the older cohorts (P ⫽ 0.0009 and 0.0490 for the 60- to
69-year and ⱖ70-year cohorts, respectively, in paired comparisons of
day 0 and day 28 titers), the fold increases were relatively small.
We also performed ELISAs using plates coated with pH1, the
entire HA molecule of the pH1N1 virus. In all cohorts, the levels of
anti-pH1 IgG before and after vaccination reflected the situation
for pH1N1-specific HAI and MN titers. On day 0, pH1-specific
IgG titers were significantly higher in the older cohorts than in the
18- to 32-year cohort (Fig. 5C). After vaccination, there was a clear
increase in pH1-specific IgG in all cohorts (P ⬍ 0.0001, P ⫽
0.0029, and P ⬍ 0.0001 for the 18- to 32-year, 60- to 69-year, and
ⱖ70-year cohorts, respectively, in paired comparisons of day 0
and day 28 titers), but this increase was most marked in the young
cohort (Fig. 5D). Notably, pH1-specific IgG was readily measurable by ELISAs in all subjects in the 18- to 32-year cohort on day 0,
even though pH1N1-specific HAI titers in the majority of these
subjects were below the limit of detection.
pH1N1 vaccination enhances serum Ab activity against a
seasonal H1N1 influenza virus in young adults. To investigate
the induction of broad anti-influenza activity by pH1N1 vaccination, we assessed the effect of vaccination on HAI and MN titers
against the heterovariant H1N1 influenza virus Bris/07, a recent
circulating seasonal strain. A more pronounced effect of vaccination on MN than on HAI activity would be consistent with the
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activity of stalk-reactive Abs, since these Abs are not detected in
the HAI assay. In all cohorts on day 0, the mean HAI and MN titers
against Bris/07 were relatively high and likely reflected recent infection or vaccination with the homologous virus (Fig. 6). Overall,

FIG 6 HAI and MN titers against the seasonal H1N1 virus Bris/07 after
pH1N1 vaccination. Bris/07-specific HAI (A) and MN (B) titers in serum were
determined on days 0 and 28 after vaccination of the indicated age cohorts (18
to 32 years, 60 to 69 years, and ⱖ70 years). Titers are shown for individual
subjects; paired titers are connected. The P values for paired comparisons of
day 0 and day 28 titers are shown.
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the effect of pH1N1 vaccination on anti-Bris/07 HAI or MN titers
was small. However, the increase in anti-Bris/07 HAI titers after
vaccination was statistically significant in the 18- to 32-year cohort. Although this was not also the case for anti-Bris/07 MN titers
in the 18- to 32-year cohort, there was a positive correlation between the fold increases in anti-Bris/07 HAI and MN titers (r ⫽
0.641, P ⫽ 0.0023). Taken together, our results point to a major
contribution of HA head-reactive, rather than stalk-reactive, Abs
to any increase in anti-Bris/07 MN titers in the young cohort.
Notably perhaps, the anti-Bris/07 HAI and MN titers on day 0 in
the 18- to 32-year cohort were inversely correlated with the fold
increases in these titers after pH1N1 vaccination (r ⫽ ⫺0.747 and
P ⫽ 0.0002 for HAI titers; r ⫽ ⫺0.565 and P ⫽ 0.0094 for MN
titers), raising the possibility that high preexisting levels of antiBris/07 Abs masked small increases in the titers of these Abs.
DISCUSSION

The goal of the current study was to relate age (and associated
differences in immune history) to the B cell response to a single
dose of inactivated 2009 pH1N1 vaccine. The subjects were analyzed in three age cohorts representing young adults through the
elderly. The cohort of young adults (aged 18 to 32 years) had little
likelihood of prior exposure to pH1N1-like viruses, which had not
circulated in human populations from approximately 1950 until
2009. An upper age limit of 32 years for this cohort ensured that
the subjects had not received the pH1N1-like swine flu vaccine in
1976. Subjects with laboratory-documented pH1N1 infection or a
recent influenza-like illness were ineligible for the study, but there
had been pH1N1 activity at the study site, and we cannot exclude
the possibility that some subjects experienced subclinical infection. However, the baseline levels of pH1N1-specific HAI and MN
Abs were very low in the young subjects in the current study,
consistent with previous studies of sera collected from young
adults prior to the emergence of the pH1N1 virus (3, 4). Thus, the
expectation was that the young cohort would have little B cell
memory for the HA of the pH1N1 virus, especially for determinants in the head region of the molecule (25). Nevertheless, a
single dose of pH1N1 vaccine elicited an effective seroresponse (a
ⱖ4-fold increase in the pH1N1-specific HAI or MN titers) in the
majority of subjects in each of the age cohorts in the current study.
Indeed, the response was significantly greater in the young cohort
than in the older cohorts. Similar results were reported elsewhere
(10–13).
A vigorous Ab response to influenza vaccination results from
the activation of preexisting memory B cells (MBCs) (15, 23). It
follows that the strong increase in the pH1N1-specific HAI titers
in the 18- to 32-year cohort after pH1N1 vaccination reflected the
activation of MBCs reactive with the HA head region. Such cells
are clearly present in these subjects (15, 26), even though preexisting pH1N1-specific HAI Abs might not be detectable. Notably,
Li and colleagues (15) demonstrated that many IgG-secreting
plasmablasts generated early in the response to pH1N1 vaccination produced Abs that bound to the HA of the H1N1 strain Bris/
07, indicating activation of cross-reactive MBCs generated by seasonal influenza viruses. Our demonstration of circulating IgG
reactive with the pH1N1 HA (pH1) in all subjects in the 18- to
32-year cohort prior to pH1N1 vaccination is consistent with the
presence of cross-reactive MBCs capable of responding to pH1,
although we did not measure the prevaccination levels of IgG reactive only with the head of pH1. There is evidence that MBCs
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have broader reactivity than long-lived ASCs generated in the response to the same antigen (27). Thus, the characteristics of circulating Abs prior to vaccination might not necessarily reflect the
potential for an MBC response. In addition, activated MBCs
might undergo additional rounds of somatic hypermutation and
selection to increase affinity for target epitopes, further distinguishing Abs accumulating in response to vaccination from those
generated previously (23, 28). Because of past exposures to
pH1N1-like viruses, the older subjects theoretically carried an
even greater number of MBCs reactive with the pH1N1 HA head
than did the young subjects. It is unclear to what extent the response to vaccination in the older cohorts was reduced by agerelated factors (29) or higher preexisting pH1N1-specific Ab levels
(30).
An early indicator of the MBC response to i.m. influenza vaccination in humans is the transient wave of circulating ASCs that
peaks after approximately 7 days (23). We evaluated this early
cellular response with the goal of relating it to the standard measurement of vaccine effectiveness, namely, the fold increase in the
HAI titer. A strong positive correlation was identified between the
peak frequency of circulating virus-specific IgG ASCs after vaccination and the magnitude of the HAI response (15). Using linear
modeling, we found that this correlation was equally strong in the
three age cohorts in our analysis. However, a given IgG ASC frequency predicted a greater fold increase in the HAI titer in the
young cohort than in the older cohorts. This relationship reflects
the response magnitude and the Ab affinity. The amount of Ab
secreted by an individual ASC is approximately the same in young
and elderly subjects (31). There is evidence that ASCs induced by
pH1N1 vaccination produce higher-affinity HA head-reactive
Abs in older subjects (13, 16), but this difference probably diminishes with affinity maturation of the response in the younger subjects. Overall, it is likely that the difference between age cohorts in
the relationship between the ASC frequency and HAI fold increase
primarily reflects a numerically greater ASC response to vaccination in the young cohort. It has been proposed that the ability of
the bone marrow to support plasma cell survival decreases with
age (32), but any impact of this on the vaccine-induced circulating
Ab levels in our analysis is unclear. Non-antigen-specific measurements of circulating plasmablast and plasma cell frequencies by
flow cytometry were much less reliable predictors of an effective
HAI response to vaccination.
The circulating virus-specific ASCs on day 7 after pH1N1 vaccination frequently included a substantial number of IgA producers in all cohorts. However, there was no associated increase in IgA
specific for the viral HA in the nasal secretions sampled on day 28.
This is consistent with evidence that virus-specific ASC numbers
in the nasal mucosa do not increase in response to i.m. influenza
vaccination (33). Mucosal homing molecules might not be expressed by IgA ASCs generated in association with the predominantly IgG response to i.m. vaccination (34). Interestingly, day 0
levels of pH1-specific IgA in nasal secretions were similar in all
cohorts, in marked contrast to the significantly higher levels of
circulating pH1-specific IgG in the older cohorts than in the
young cohort. In part, this might reflect a difference in the duration of systemic IgG and mucosal IgA production after influenza
infection or prior vaccination (35).
Recent studies demonstrated that infection or vaccination with
the 2009 pH1N1 virus favors induction of broadly cross-reactive
HA-specific Abs, including Abs reactive with the HA stalk (14–

cvi.asm.org 873

Sangster et al.

18). Importantly, our analysis adds to the limited available information on circulating levels of stalk-reactive Abs before and after
pH1N1 exposure. We measured the stalk-reactive Abs by ELISAs
using the chimeric cH6/1 HA (consisting of the H6 head domain
and the H1 stalk domain) as a coating reagent. Other studies using
this strategy found little serum reactivity to cH6/1 in young adults
without exposure to pH1N1 or an antigenically related virus (17,
22), whereas our preliminary experiments demonstrated a range
of cH6/1 binding levels in sera from healthy donors. On day 0 in
the current analysis, stalk-reactive IgG was clearly present in all
subjects in the 18- to 32-year cohort, and the titers were significantly higher in the older cohorts. Consistent with this, Khurana
and colleagues (13) identified Abs reactive with the HA stalk region in subjects prior to pH1N1 vaccination, including subjects
seronegative for the virus. Sui and colleagues (36) showed that
sera from non-H5-exposed subjects contained H5-reactive IgG as
well as Abs that bound to group 1 HA stalks. Notably, the titers of
H5-reactive IgG, which might largely reflect binding to the HA
stalk (37), were comparable to the anti-cH6/1 titers in our analysis. H5-reactive and group 1 HA stalk-reactive Abs have also been
demonstrated in intravenous immunoglobulin (IVIG), consisting
of pooled IgG from thousands of (most likely) H5-naive individuals (36, 38). The presence of H5-binding Abs in pooled sera from
adults but not from children suggests progressive acquisition with
increasing age and influenza exposure (38). There is evidence that
seasonal influenza viruses induce at least some stalk-reactive Ab
production (16, 39, 40). Occasionally, a more marked increase in
titers might occur, depending on the form of exposure and degree
of HA novelty. This process is likely to contribute to the day 0
levels of stalk-reactive Abs measured in our analysis and also to
account for the higher titers in older cohorts. It might be relevant
that many study subjects received the seasonal influenza vaccine 2
to 5 months prior to the pH1N1 vaccine. Notably perhaps, in the
18- to 32-year cohort, there was a modest correlation between day
0 HAI titers against Bris/07 (a component of the seasonal vaccine)
and day 0 titers of anti-stalk Abs (r ⫽ 0.458, P ⫽ 0.042), consistent
with some anti-stalk Ab induction by the seasonal vaccine.
The pH1N1 vaccine elicited a highly significant increase in antistalk Ab levels in the 18- to 32-year cohort, but this effect was
much less pronounced in the older cohorts. These findings are
consistent with current models relating the strength of the responses to conserved epitopes, such as stalk determinants, with
the novelty of the HA (14–16). It is suggested that an individual
exposed to a succession of related HAs develops a growing population of MBCs reactive with immunodominant (and variable)
head epitopes. As these cells become abundant, they outcompete
less frequent MBCs specific for conserved epitopes and come to
dominate the Ab responses to related HAs, accounting for the
largely strain-specific responses to seasonal influenza viruses. The
situation is altered when an individual is exposed to an HA with
head epitopes that are substantially different from those experienced previously; MBCs specific for conserved epitopes are then
freed from competitive restraints and contribute to the HA-specific Ab response. Our results for the young cohort after pH1N1
vaccination fit with the latter scenario, whereas the HA head-focused responses in the older cohorts are consistent with activation
of predominantly head-reactive MBCs generated by past exposures to pH1N1-like viruses. It is noteworthy that the 18- to 32year cohort not only produced stalk-reactive Abs but also generated a vigorous response to the head of the pH1N1 HA (as
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measured by HAI titers). Thus, stalk-reactive Ab production is not
completely inhibited by the presence of an apparently substantial
MBC population reactive to HA head determinants.
The vigorous response to pH1N1 vaccination with the production of anti-stalk Abs in the 18- to 32-year cohort suggested that
broad anti-influenza activity might also be increased. We assessed
this by evaluating changes in the HAI and MN activity against the
seasonal H1N1 strain A/Bris/07. The sensitivity of this analysis was
probably limited in subjects with high preexisting HAI and MN
titers against Bris/07. However, in the subjects with low preexisting anti-Bris/07 HAI and MN titers, the trend was for an increase
in anti-Bris/07 activity after pH1N1 vaccination, consistent with a
broadening of protection. Notably, an increase in the anti-Bris/07
MN titer was generally associated with an increase in the antiBris/07 HAI titer. This suggests an effect due predominantly to
cross-reactive Abs against the HA head determinants, since stalkreactive Abs would be detected only by the MN assay, whereas the
head-reactive Abs that mediate HAI are also likely to be neutralizing. Our observations fit with recent studies demonstrating that
the HA-specific Abs generated by pH1N1 vaccination include not
only stalk-reactive Abs but also head-reactive Abs with activity
against a range of H1N1 variants (14, 15).
In summary, our analysis provides a comprehensive picture of
the B cell response to a pH1N1 vaccine in age cohorts differing in
their history of exposure to pH1N1-like viruses. One goal was to
establish associations between the serological, cellular, and mucosal aspects of the response. Importantly, we analyzed the pre- and
postvaccination levels of Abs reactive with the HA stalk and asked
whether changes in these levels related to a broadening of antiinfluenza activity. It has been proposed that the induction of
cross-reactive anti-stalk Abs by pH1N1 during the 2009 pandemic
boosted immunity to seasonal H1N1 viruses and contributed to
their disappearance (41). In our analysis, stalk-reactive Ab levels
in the young cohort were significantly increased after pH1N1 vaccination, but this was not associated with increased neutralizing
activity against a seasonal influenza virus. Perhaps the increase in
anti-stalk Ab levels is greater following pH1N1 infection than following vaccination. Another possibility is that the MN assay used
in our study was less sensitive for detecting influenza neutralization by stalk-reactive than by head-reactive Abs (39). In addition,
the MN assay strategy allowed for only a single cycle of viral replication and thus was limited to the detection of Abs that block cell
infection. This approach would not have detected anti-stalk Abs
that act at later stages in the production of infectious viruses (42).
Functional analyses of anti-stalk Abs will be facilitated by the recent development of recombinant viruses expressing chimeric HA
molecules with exotic head domains (22). Nevertheless, our analysis emphasizes the need to clearly establish the relationship between circulating stalk-reactive Ab levels and resistance to influenza. This is particularly important in light of the recent intense
interest in the development of broadly protective influenza vaccines based on the induction of stalk-reactive Abs (43).
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